IN8bio, Inc (INAB) Appoints Jeremy Graff to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
- Twilio, Vylor set to join S&P 500 as index reshuffles members
IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors
May 1, 2023 8:00 AM EDTDr. Jeremy Graff spent 17 years at Eli Lilly and Company, where he built and led the translational oncology group, supporting and advancing 31 clinical assets in Eli Lillys oncology portfolioHe is a highly respected industry leader in oncology with a track record of success in advancing multiple novel anti-cancer compounds into and through the clinic and has been instrumental in garnering the approval of several oncology products
NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq:... More
